Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Ibogaine/Neuroimaging & Brain Measures

Ibogaine for Neuroimaging & Brain Measures

7 papers and 0 clinical trials exploring ibogaine as a treatment for neuroimaging & brain measures.

CompoundIndole Alkaloid

Ibogaine

A unique indole alkaloid with complex pharmacology, investigated primarily for its capacity to interrupt substance use disorders and withdrawal.

Full Ibogaine profile
IndicationApproximately 264 million people globally suffer from depression, with PTSD affecting around 8 million adults in the United States each year.

Neuroimaging & Brain Measures

Recent advances in neuroimaging have shed light on the neurobiological mechanisms underlying the effects of psychedelics, particularly in the treatment of mental health disorders such as depression and PTSD. Studies involving compounds like psilocybin and MDMA have demonstrated significant changes in brain activity associated with therapeutic outcomes.

Full Neuroimaging & Brain Measures profile

Academic Research

7 papers
Open Accessindividual

Increased cortical thickness and decreased brain age among special operations veterans with blast TBI after a magnesium-ibogaine protocol

This secondary analysis of an observational study (n=30) - named MISTIC - of Special Operations Forces veterans with blast-related traumatic brain injury, examined ibogaine given with magnesium and found increased cortical thickness, larger subcortical volumes and a lower estimated brain age one month later. The authors note that the MRI changes could reflect neuroplastic effects, although the scans may also be influenced by non-structural factors.

Published
February 21, 2026
Journal
iScience
Authors
Geoly, A. D., Coetzee, J. P., Buchanan, D. M., Struckmann, W., Kim, B., Sridhar, M., Azeez, A., Lissemore, J. I., Cherian, K., Faerman, A., Keynan, J. N., Singal, P., Shanbour, A., Bandeira, I. D., Kratter, I. H., Adamson, M. M., Saggar, M., Rolle, C., Williams, N. R.
Paywallindividual

Mystical experiences during magnesium-Ibogaine are associated with improvements in PTSD symptoms in veterans

This secondary analysis of an open-label study (n=30) of male Veterans with traumatic brain injury found that greater intensity of mystical experiences during magnesium-ibogaine treatment was associated with larger reductions in PTSD severity both immediately and one month post-treatment, as well as greater reductions in peak alpha frequency at one month.

Published
February 1, 2026
Journal
Journal of Affective Disorders
Authors
Brown, R. E., Lissemore, J. I., Shinozuka, K. F., Coetzee, J. P., Faerman, A., Olash, C. A., Geoly, A. D., Buchanan, D. M., Cherian, K. N., Chaiken, A., Shamma, A., Sridhar, M., Hunegnaw, S. A., Johnson, N. D., Rolle, C. E., Adamson, M. M., Williams, N. R.
Paywallindividual

Magnesium-ibogaine therapy effects on cortical oscillations and neural complexity in veterans with traumatic brain injury

This analysis of an open-label observational study (n=30) found that magnesium-ibogaine therapy in combat veterans with traumatic brain injury (TBI) led to slower brain wave patterns and reduced neural complexity on EEG, which correlated with improvements in PTSD, anxiety, and cognitive function at one-month follow-up.

Published
July 24, 2025
Journal
Nature Mental Health
Authors
Lissemore, J. I., Chaiken, A., Keller, C. J., Williams, N. R., Cherian, K. N., Buchanan, D., Espil, F., Keynan, J. N., Sridhar, M., Rolle, C. E., Saggar, M.
Open Accessmeta

Neuroimaging in psychedelic drug development: Past, present, and future

This review (2023) discusses the emerging field of psychedelic therapy for psychiatric disorders, emphasizing the potential of classic serotonergic psychedelics like psilocybin and LSD and substances like ketamine, MDMA, and ibogaine. It highlights the role of advanced neuroscientific research methods, particularly neuroimaging using Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI), in advancing the understanding of drug and therapy effects on the brain. The article identifies key knowledge gaps, including the relationship between acute and longer-term effects, the precise characterization of effects at the 5-HT2A receptor, and the impact of these compounds on neuroplasticity, and proposes a roadmap for future research to address these questions through multimodal PET/MRI studies.

Published
September 27, 2023
Journal
Molecular Psychiatry
Authors
Wall, M. B., Harding, R., Zafar, R., Rabiner, E. A., Nutt, D. J., Erritzoe, D.
Open Accessindividual

EEG Gamma Band Alterations and REM-like Traits Underpin the Acute Effect of the Atypical Psychedelic Ibogaine in the Rat

This rat study (n=54) investigated the acute effects of ibogaine (12mg/0.3kg) with intracranial electroencephalography and computational assessment of brain states related to sleep and wakefulness. Results indicated that ibogaine induces REM sleep traits during wakefulness and NREM sleep, which are driven by local power increases of gamma oscillations. This provides evidence that ibogaine's effects are psychedelic in so far that it enhances dream-like states of waking consciousness.

Published
January 11, 2021
Journal
ACS Pharmacology and Translational Science
Authors
González, J., Cavelli, M., Castro-Zaballa, S., Mondino, A., Tort, A. B., Rubido, N., Carrera, I., Torterolo, P.
Paywallindividual

Ibogaine Acute Administration in Rats Promotes Wakefulness, Long-Lasting REM Sleep Suppression, and a Distinctive Motor Profile

This rat study (n=26) investigated the effects of ibogaine (20 and 40 mg/kg) on the states of sleep and wakefulness in rats and found that it promotes a waking state that was accompanied by a decrease in the total amount of SWS and REM sleep, in a similar pattern as traditional psychedelics.

Published
April 27, 2018
Journal
Frontiers in Pharmacology
Authors
Baumann, M. H., Carrera, I., Scorza, C., González, J., Prieto, J. P., Rodríguez, P., Cavelli, M., Benedetto, L., Mondino, A., Pazos, M., Seoane, G., Torterolo, P.

Clinical Trials

0 trials

No clinical trials have been tagged with both Ibogaine and Neuroimaging & Brain Measures yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all Ibogaine papers Search all Neuroimaging & Brain Measures trials Full Ibogaine profile Full Neuroimaging & Brain Measures profile